



MAPS

Bulletin of the Multidisciplinary Association for Psychedelic Studies

- 3** July 1997 **Letter** from...
Rick Doblin, MAPS President

RESEARCH UPDATES:

- 5** New research with **MDMA** to look at serotonin and dopamine system interactions
Manuel Tancer, M.D. & Charles R. Schuster, Ph.D.
- 12** **Ketamine** Research: From Yale to the Lab in St. Petersburg
Evgeny Krupitsky, M.D., Ph.D.
- 13** Israel: A Cognitive-Psychological Study of **Ayahuasca**
Benny Shanon, Ph.D.
- 16** Two new applications to NIH for research into the medical utility of marijuana
Cannabis in Acute Migraine Treatment Project
Ethan Russo, M.D.
- Abrams protocol submitted anew: Short-term effects of **cannabinoids** in HIV patients
Donald Abrams, M.D.

FEATURED ARTICLES:

- 18** Treatment of Childhood Schizophrenia Utilizing **LSD** and **Psilocybin**
Gary Fisher, Ph.D.
- 26** Ethical **Care** in Psychedelic Work
Kylea Taylor, M.S.

CONFERENCE HIGHLIGHTS:

- 31** Hallucinogenic **Drugs** in Experimental Psychiatric Research
 Vaals, Netherlands—March 13-15, 1997
Julie Holland, M.D.
 Comments by **Sylvia Thyssen**
- 37** The **Hofmann** Report
Myron Stolaroff, M.A.
- 43** The **Heffter** Research Institute Update
David E. Nichols, Ph.D.

BOOK REVIEWS:**44 Non-Anglo Entheography: Mini-Reviews of Non-English Publications****Jonathan Ott**

51

Searching for Magic Bullets: Orphan Drugs, Consumer Activism, and Pharmaceutical Development,
Basara, L.R. and Montagne, M.*Clinical Research in Pharmaceutical Development,*
Bleidt, B. and Montagne, M.**June Riedlinger, R.Ph., Pharm.D.****52 The Literature of Psychedelics****Bob Wallace****MAPS FORUM****54 Announcements****55 Hello from MAPS' new staffperson****Carla Higdon****56 MAPS Membership and Renewal Information****The Interview with Dr. Albert Hofmann**

has been postponed until the Fall 1997 issue of the MAPS Bulletin. We apologize for the delay.

MAPS' NEW ADDRESS

MAPS (Multidisciplinary Association for Psychedelic Studies)
2121 Commonwealth Avenue
Suite 220

Charlotte, NC 28205

• Phone: (704) 334-1798

• Fax: (704) 334-1799

• Internet: info@maps.org• www.maps.org

ISSN 1080-8981

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist psychedelic researchers around the world design, obtain governmental approval, fund, conduct and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax deductible donations. MAPS has previously funded basic scientific research into the safety of MDMA (3,4, methylenedioxymethamphetamine, *Ecstasy*) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining government approval for their medical uses. Interested parties wishing to copy any portion of this newsletter are encouraged to do so and are kindly requested to credit MAPS including name and address. The MAPS newsletter is produced by a small group of dedicated staff and volunteers. Your participation, financial or otherwise, is welcome. © 1997 Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS) 2121 Commonwealth Avenue, Suite 220, Charlotte, NC 28205. Phone: (704) 334-1798. Fax: (704) 334-1799. Internet: info@maps.org, and <http://www.maps.org>

Printed on recycled paper